
Feature|Articles|July 10, 2026
Midyear 2026 recap: Major clinical findings in optometry
Author(s)Abigail Lewis, Content Intern
A midyear look at 2026's biggest optometry findings, from myopia control research to safety signals on red light therapy and semaglutide.
Advertisement
Advertisement
The first half of 2026 delivered a wave of research relevant to myopia management, spanning spectacle lens design, treatment tapering strategies, and mechanistic questions about why myopia progresses. A safety evaluation of red light therapy devices and a case report linking semaglutide to rapid diabetic retinopathy (DR) progression round out a busy 6 months for ODs managing both pediatric and adult patients. Below is a summary of the major findings optometrists should know heading into the second half of the year.
Related to this article

Kevin Chan, OD, MS, FAAO, FBCLA, IACMM, stated in his Rapid Fire lecture that high myopes shouldn't be counted out of orthokeratology treatment.

Mohammad Rafieetary, OD, FAAO, FORS, DipABO, ABCMO, details his AAOpt 2026 presentation "Photobiomodulation in Age-Related Macular Degeneration: Evidence, Mechanisms, and Clinical Integration."

Magdalena Stec, OD, FAAO, and Noreen Shaikh, OD, MEd, FAAO, gave an overview of current evidence-based myopia control treatments in part of their AAOpt 2026 session.

Raman Bhakhri, OD, FAAO, details a session given with Denise Skiadopoulos, OD, FAAO, during the annual AAOpt meeting in Anaheim, California.

Sherrol Reynolds, OD, FAAO, details her session "GLP-1RAs and Ocular Health: AOA Guidance for Optometric Practice 2025" during AAOpt 2026.

Magdalena Stec, OD, FAAO; Noreen Shaikh, OD, FAAO; Huizi Kelly Yin, OD, FAAO; and Brenda Bohnsack, MD, PhD, detail their AAOpt 2026 session in Anaheim, California.

Lloyd Williams, MD, PhD, discusses rising cataract blindness and low-cost surgery in conflict zones for World Sight Day.
Advertisement
Advertisement

